NASDAQ:CNTA

Centessa Pharmaceuticals (CNTA) Stock Forecast, Price & News

$5.99

-0.10 (-1.64%)

(As of 10:50 AM ET)

Compare

Today's Range: $5.88
▼
$6.09
50-Day Range: $6.10
▼
$7.97
52-Week Range: $3.00
▼
$8.65

Volume: 45,334 shs
Average Volume: 158,158 shs
Market Capitalization: $583.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Centessa Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 41.9% Upside
$8.50 Price Target
Short Interest: Healthy
2.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.74) to ($1.76) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

409th out of 966 stocks

Pharmaceutical Preparations Industry

177th out of 448 stocks

3.3

Analyst's Opinion

Consensus Rating
Centessa Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, Centessa Pharmaceuticals has a forecasted upside of 41.9% from its current price of $5.99.
Amount of Analyst Coverage
Centessa Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.25% of the float of Centessa Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Centessa Pharmaceuticals has a short interest ratio ("days to cover") of 8.
Change versus previous month
Short interest in Centessa Pharmaceuticals has recently decreased by 29.73%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Centessa Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Centessa Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CNTA.

3.3

News and Social Media Coverage

News Sentiment
Centessa Pharmaceuticals has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Centessa Pharmaceuticals this week, compared to 1 article on an average week.
MarketBeat Follows
5 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Centessa Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.54% of the stock of Centessa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
73.92% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Centessa Pharmaceuticals are expected to decrease in the coming year, from ($1.74) to ($1.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Centessa Pharmaceuticals is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Centessa Pharmaceuticals is -3.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Centessa Pharmaceuticals has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

CNTA Price History

30 days | 90 days | 365 days | Advanced Chart

CNTA Stock News Headlines

September 1, 2023 | msn.com

Centessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 15.30% to 8.33

August 31, 2023 | finance.yahoo.com

Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 22, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 31, 2023 | finance.yahoo.com

Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 23, 2023 | finance.yahoo.com

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

August 17, 2023 | msn.com

Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated

August 16, 2023 | msn.com

Guggenheim Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Buy Recommendation

August 16, 2023 | msn.com

SVB Securities Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Outperform Recommendation

September 22, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 15, 2023 | markets.businessinsider.com

Where Centessa Pharmaceuticals Stands With Analysts

August 14, 2023 | finance.yahoo.com

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

July 10, 2023 | finance.yahoo.com

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

July 6, 2023 | msn.com

Centessa Pharmaceuticals plc - ADR (CNTA) Price Target Increased by 8.76% to 6.55

June 22, 2023 | msn.com

Evercore ISI Group Initiates Coverage of Centessa Pharmaceuticals plc - ADR (CNTA) with Outperform Recommendation

June 13, 2023 | msn.com

Guggenheim Initiates Coverage of Centessa Pharmaceuticals plc - ADR (CNTA) with Buy Recommendation

May 23, 2023 | finanznachrichten.de

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

May 22, 2023 | markets.businessinsider.com

Centessa Pharma Announces FDA's Decision To Grant Fast Track Designation For SerpinPC

May 22, 2023 | finance.yahoo.com

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

May 22, 2023 | seekingalpha.com

Centessa Pharmaceuticals: Highly Diversified With Decent Cash, Good Data, No Near-Term Catalysts

May 15, 2023 | msn.com

Goldman Sachs Maintains Centessa Pharmaceuticals plc - ADR (CNTA) Neutral Recommendation

May 12, 2023 | msn.com

Centessa Pharmaceuticals: Q1 Earnings Insights

May 12, 2023 | finance.yahoo.com

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

April 27, 2023 | finance.yahoo.com

Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22%

April 1, 2023 | seekingalpha.com

Centessa Pharmaceuticals GAAP EPS of -$0.45 misses by $0.01

March 30, 2023 | finance.yahoo.com

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

March 23, 2023 | finance.yahoo.com

Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

March 23, 2023 | finance.yahoo.com

Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings?

See More Headlines

Receive CNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNTA Company Calendar

Last Earnings: 8/14/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CNTA
CUSIP: N/A
CIK: 1847903
Web: www.centessa.com
Phone: 44-73-9178-9784
Fax: N/A
Employees: 64
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.50
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +41.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-216,210,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -54.00%
Return on Assets: -40.14%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 10.35
Quick Ratio: 10.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.55 per share
Price / Book: 1.69

Miscellaneous

Outstanding Shares: 97,400,000
Free Float: 86,163,000
Market Cap: $583.43 million
Optionable: Not Optionable
Beta: 1.27

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Saurabh Saha M.D. (Age 46)
Ph.D., CEO & Director
Comp: $957.67k

Dr. Gregory M. Weinhoff M.B.A. (Age 52)
M.D., MBA, Principal Accounting Officer & CFO
Comp: $655k

Dr. David M. Chao Ph.D. (Age 55)
Chief Admin. Officer
Comp: $655k

Ms. Tia L. Bush (Age 52)
Chief Technology & Quality Officer

Ms. Kristen K. Sheppard Esq.
J.D., Sr. VP of Investor Relations & Corp. Communications

Mr. Iqbal J. Hussain L.L.B. (Age 42)
Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Ms. Karen M. Anderson (Age 55)
Chief People Officer

Dr. Antoine Yver M.D. (Age 65)
M.Sc., MSc, Exec. VP & Chairman of Devel.

Dr. David John Grainger Ph.D. (Age 54)
Chief Innovation Officer

Dr. Harris L. Rotman Ph.D.
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CNTA Stock - Frequently Asked Questions

Should I buy or sell Centessa Pharmaceuticals stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNTA shares.
View CNTA analyst ratings or view top-rated stocks.
What is Centessa Pharmaceuticals' stock price forecast for 2023?: 7 Wall Street analysts have issued 12 month price objectives for Centessa Pharmaceuticals' stock. Their CNTA share price forecasts range from $4.00 to $15.00. On average, they expect the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 41.9% from the stock's current price.
View analysts price targets for CNTA or view top-rated stocks among Wall Street analysts.
How have CNTA shares performed in 2023?: Centessa Pharmaceuticals' stock was trading at $3.10 at the beginning of 2023. Since then, CNTA stock has increased by 93.2% and is now trading at $5.99.
View the best growth stocks for 2023 here.
Are investors shorting Centessa Pharmaceuticals?: Centessa Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,300,000 shares, a drop of 29.7% from the August 15th total of 1,850,000 shares. Based on an average trading volume of 162,800 shares, the short-interest ratio is presently 8.0 days. Approximately 2.3% of the shares of the company are sold short.
View Centessa Pharmaceuticals' Short Interest.
When is Centessa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our CNTA earnings forecast.
How were Centessa Pharmaceuticals' earnings last quarter?: Centessa Pharmaceuticals plc (NASDAQ:CNTA) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.17.

When did Centessa Pharmaceuticals IPO?: (CNTA) raised $285 million in an initial public offering on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.
What is Centessa Pharmaceuticals' stock symbol?: Centessa Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNTA."
Who are Centessa Pharmaceuticals' major shareholders?: Centessa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (2.10%), Affinity Asset Advisors LLC (0.95%), Tanager Wealth Management LLP (0.73%), Woodline Partners LP (0.72%), BlackRock Inc. (0.31%) and Platinum Investment Management Ltd. (0.18%). Insiders that own company stock include (Bermuda) Ltd Gap, Aaron Kantoff, Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Iqbal J Hussain, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha, Thomas Templeman and Tia L Bush.
View institutional ownership trends.
How do I buy shares of Centessa Pharmaceuticals?: Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Centessa Pharmaceuticals' stock price today?: One share of CNTA stock can currently be purchased for approximately $5.99.
How much money does Centessa Pharmaceuticals make?: Centessa Pharmaceuticals (NASDAQ:CNTA) has a market capitalization of $583.43 million. The company earns $-216,210,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.
How can I contact Centessa Pharmaceuticals?: Centessa Pharmaceuticals' mailing address is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. The official website for the company is www.centessa.com. The company can be reached via phone at 44-73-9178-9784 or via email at investorrelations@centessa.com.

This page (NASDAQ:CNTA) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial